Steven P. Cole

Research Designs, Inc., Yorktown Heights, NY

Context. Neuropathic pain (NP) from peripheral neuropathy (PN) arises from ectopic firing of unmyelinated C-fibers with accumulation of sodium and calcium channels. Because pulsed electromagnetic fields (PEMF) safely induce extremely low frequency (ELF) quasirectangular currents that can depolarize, repolarize, and hyperpolarize neurons, it was hypothesized that directing this energy into the sole of one foot could potentially modulate neuropathic pain. Objective. To determine if 9 consecutive 1-h treatments in physician’s office (excluding weekends) of a pulsed signal therapy can reduce NP scores in refractory feet with PN. Design/setting/patients. 24 consecutive patients with refractory and symptomatic PN from diabetes, chronic inflammatory demyelinating polyneuropathy (CIDP), pernicious anemia, mercury poisoning, paraneoplastic syndrome, tarsal tunnel, and idiopathic sensory neuropathy were enrolled in this nonplacebo pilot study. The most symptomatic foot received therapy. Primary endpoints were comparison of VAS scores at the end of 9 days and the end of 30 days follow-up compared to baseline pain scores. Additionally, Patients’ Global Impression of Change (PGIC) questionnaire was tabulated describing response to treatment. Subgroup analysis of nerve conduction scores, quantified sensory testing (QST), and serial examination changes were also tabulated. Subgroup classification of pain (Serlin) was utilized to determine if there were disproportionate responses. Intervention. Noninvasive pulsed signal therapy generates a unidirectional quasirectangular waveform with strength about 20 gauss and a frequency about 30 Hz into the soles of the feet for 9 consecutive 1-h treatments (excluding weekends). The most symptomatic foot of each patient was treated. Results. All 24 feet completed 9 days of treatment. 15/24 completed follow-up (62%) with mean pain scores decreasing 21% from baseline to end of treatment (P = 0.19) but with 49% reduction of pain scores from baseline to end of follow-up (P < 0.01). Of this group, self-reported PGIC was improved 67% (n = 10) and no change was 33% (n = 5). An intent-to-treat analysis based on all 24 feet demonstrated a 19% reduction in pain scores from baseline to end of treatment (P = 0.10) and a 37% decrease from baseline to end of follow-up ( P < 0.01). Subgroup analysis revealed 5 patients with mild pain with nonsignificant reduction at end of follow-up. Of the 19 feet with moderate to severe pain, there was a 28% reduction from baseline to end of treatment (P < 0.05) and a 39% decrease from baseline to end of follow-up (P < 0.01). Benefit was better in those patients with axonal changes and advanced CPT baseline scores. The clinical examination did not change. There were no adverse events or safety issues. Conclusions. These pilot data demonstrate that directing PEMF to refractory feet can provide unexpected shortterm analgesic effects in more than 50% of individuals. The role of placebo is not known and was not tested. The precise mechanism is unclear yet suggests that severe and advanced cases are more magnetically sensitive. Future studies are needed with randomized placebo-controlled design and longer treatment periods.

Key Words: Neuropathic pain • Pulsed magnetic field therapy • Peripheral neuropathy

References

1. Low PA, Dotson RM. Symptomatic treatment of painful neuropathy (Editorial). JAMA 1998; 280: 1863-1864.[Free Full Text]
2. Baron R. Peripheral neuropathic pain. from mechanisms to symptoms. Clin J Pain 2000; 16: S16-S20.
3. Waxman SG. The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contribution to hyperexcitability of primary sensory neurons. Pain 1999;Suppl 6: S133-S140.
4. Eglen RM, Hunter JC, Dray A. Ions in the fire: recent ionchannel research and approaches to pain therapy. Trends Pharmacol Sci 1999; 20: 337-342.[CrossRef][ISI][Medline] [Order article via Infotrieve]
5. Liboff AR, Smith SD, McLeod BR. Comment on "clarification and application of an ion parametric resonance model for magnetic field interactions with biological sysems." Bioelectromagnetism 1995; 16: 272-273.
6. Bassett CAL. Low energy pulsing electromagnetic fields modify biomedical processes. Bioassays 1987; 6: 36-42.[ISI][Medline] [Order article via Infotrieve]
7. Bassett CAL. Fundamental and practical aspects of therapeutic uses of pulsed electro-magnetic fields (PEMFs). Crit Rev Biomed Eng 1989; 17: 451-529.[ISI][Medline] [Order article via Infotrieve]
8. O’Brien WJ, Murray HM, Orgel MG. Effects of pulsing electromagnetic fields on nerve regeneration. Correlation of electrophysiologic and histochemical parameters. J Bioelec 1984; 3: 33-40.[ISI]
9. Reilly JP. Peripheral nerve stimulation by induced electric currents: exposure to time-varying magnetic fields. Med Biol Eng Comput 1989; 27: 101-110.[ISI][Medline] [Order article via Infotrieve]
10. Olney RK, So YT, Goodin DS, Aminoff MJ. A comparison of magnetic and electrical stimulation of peripheral nerves. Muscle Nerve 1990; 13: 957-963.[ISI][Medline] [Order article via Infotrieve]
11. Pomeranz B, Campbell JJ. Weak electric current accelerates motorneurons regeneration in sciatic nerves of 10-monthold rats. Brain Res 1993; 603: 271-278.[CrossRef][ISI][Medline] [Order article via Infotrieve]
12. Sisken BF, Kanje M, Lundborg G, et al. Stimulation of rat sciatic nerve regeneration with pulsed electromagnetic fields. Brain Res 1989; 485: 309-316.[CrossRef][ISI][Medline] [Order article via Infotrieve]
13. Farrar JT, Young JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11- point numerical pain rating scale. Pain 2001; 94: 149-158.[CrossRef][ISI][Medline] [Order article via Infotrieve]
14. Weintraub MI, Cole SP. Pulsed magnetic field therapy in refractory carpal tunnel syndrome: electrodiagnostic parameters—pilot study. (Under review, Clinical Neurophysiology)
15. Markoll R. Pulsed signal therapy for the treatment of osteoarthritis: double-blind and randomized study results in 50,000 patients. Ann Rheum Dis 2000; 59(Suppl 1): 131.
16. Trock DH. Electromagnetic fields and magnets. Rheumatol Rheumatic Dis Clin NA 2000; 26: 51-62.
17. Wilson DH, Jagadeesh MB, Newman PP, et al. The effects of pulsed electromagnetic energy on peripheral nerve regeneration. Ann N Y Acad Sci 1974; 238: 575-580.[ISI][Medline] [Order article via Infotrieve]
18. Macias MY, Battolletti JH, Sutton CH, et al. Directed and enhanced neurite growth with pulsed magnetic field stimulation. Bioelectromagnetics 2000; 21: 272-286.[CrossRef][ISI][Medline] [Order article via Infotrieve]
19. Ito H, Bassett CAL. Effect of weak, pulsing electromagnetic fields on neural regeneration in the rat. Clin Orthoped Related Res 1983; 181: 283-290.
20. Ehrlicher A, Betz T, Stuhrmann B, et al. Guiding neuronal growth with light. Proc Natl Acad Sci U S A 2002; 99: 16024-16028.[Abstract/Free Full Text]
21. Nordin M, Nystrom B, Wallin U, Hagbarth KE. Ectopic sensory discharges and paresthesiae in patients with disorders of peripheral nerves, dorsal roots and dorsal columns. Pain 1984; 20: 231-245.[CrossRef][ISI][Medline] [Order article via Infotrieve]
22. Ochoa JL, Torebjork HE. Paresthesiae from ectopic impulse generation in human sensory nerves. Brain 1980; 103: 835-853.[ISI][Medline] [Order article via Infotrieve]
23. Weintraub MI, Wolfe GI, Barohn RA, et al. Static magnetic field therapy for symptomatic diabetic neuropathy: a randomized, double-blind, placebo-control trial. Arch Phys Med Rehab 2003; 84: 736-746.[CrossRef][ISI][Medline] [Order article via Infotrieve]
24. Asbury AK, Thomas PK, eds. Peripheral nerve disorders 2. Oxford, UK: Butterworth Heinemann; 1995.
25. Segal NA, Toda Y, Huston J, et al. Two configurations of static magnetic fields for treating rheumatoid arthritis of the knee: a double-blind clinical trial. Arch Phys Med Rehab 2001; 82: 1452-1460.
26. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of Tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1842-1846.[Abstract]
27. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized control trial. JAMA 1998; 280: 1831-1836.[Abstract/Free Full Text]
28. Wall PI, Melzack R. Textbook of pain, 4th ed. Edinburgh: Churchill Livingstone; 1999